Back to Rare Disease
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT01355913

NCT01355913
Completed Not Applicable

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with myelodysplastic syndrome (MDS), a condition affecting blood cell production in the bone marrow, confirmed through laboratory testing of cells.
  • You have symptoms or test results that suggest you may have myelodysplastic syndrome (MDS), even if it has not been fully confirmed yet.
  • You are over 18 years old.

Who may not be able to join:

  • No specific exclusion criteria were listed in the official information provided (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Completed
Phase
Not Applicable
Sponsor
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Registry
clinicaltrials_gov
Start date
1 October 2008
Est. completion
1 October 2016

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Screening and genetic monitoring of patients with MDS under different treatment modalities by cytogenetic analyses of circulating CD34+cells.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov